Dr. Lal Pathlabs Ltd. News and Updates

Name: Latest research reports of Dr. Lal Pathlabs Ltd. authored by Geojit BNP Paribas and published by - Trendlyne research reports.
Item: Dr. Lal Pathlabs Ltd.
Rating: 4
Author: Geojit BNP Paribas

Keep track of all breaking news on Dr. Lal Pathlabs Ltd. from all sources in a single place.

Load latest

Dr. Lal Pathlabs Ltd.

19 Aug 2021

3179.60

1.66%

Trade Spotlight: What should investors do with Dr Lal Pathlabs MindTree?

Moneycontrol

Dr Lal Pathlabs that rose 4 percent and MindTree gained around 6 percent on August 18 to hit a fresh 52-week high

Dr. Lal Pathlabs Ltd. is trading below its 30 day SMA of 3270.0

Dr. Lal Pathlabs Ltd.

05 Aug 2021

3179.60

1.66%

DR. LAL PATHLABS LIMITED

Accumulate: Dr. Lal Pathlabs Ltd.

Target

Geojit BNP Paribas

With persistent focus of service parameters and timely turnarounds, DLPL was able to achieve robust growth in volume during the pandemic. Leveraging its dedicated network driven infrastructure and techenabled processes, we expect the company to be able to perform well in the expected third wave situation. Hence, we upgrade our rating on the...

Dr. Lal Pathlabs Ltd. has an average target of 3111.40 from 5 brokers.

Dr. Lal Pathlabs Ltd.

04 Aug 2021

3179.60

1.66%

Dr Lal's growth prospects may be priced in the stock

livemint

The company has adequately diversified its revenue stream, expanding into areas beyond the Delhi-NCR region

Dr. Lal Pathlabs Ltd. is trading above its 200 day SMA of 2892.1

Dr. Lal Pathlabs Ltd.

03 Aug 2021

3179.60

1.66%

Company Update - Valuation running way ahead of fundamentals - SELL

Sell: Dr. Lal Pathlabs Ltd.

Target

Prabhudas Lilladhar

unsustainable rise in volume of patients and samples (all time high) We reinitiate coverage on DLPL stock with Sell' rating, previously kept Under Review'. 1QFY22 earnings were higher than our estimates solely driven by additional volumes, due to large number of patients in the second wave. Business in core portfolio grew 15% YoY given 1) all collection centers and labs resumed operations much earlier than expected 2) high revenue...

Dr. Lal Pathlabs Ltd. has gained 26.39% in the last 6 Months

Dr. Lal Pathlabs Ltd.

30 Jul 2021

3179.60

1.66%

Dr Lal PathLabs Q1 net profit zooms nearly 5-fold to Rs 133.7 crore

Moneycontrol

The company had posted a net profit of Rs 28.4 crore for the corresponding period of the previous fiscal, Dr Lal PathLabs said in a regulatory filing.

Number of FII/FPI investors decreased from 382 to 358 in Jun 2025 qtr

Dr. Lal Pathlabs Ltd.

19 Jun 2021

3179.60

1.66%

U'khand Police sets up SIT to probe fake Covid testing during Kumbh

Business Standard

The Uttarakhand Police has set up a special investigation team to probe allegations that fake Covid tests were conducted during the Haridwar Kumbh Mela. One of the world's largest religious gatherings, the Kumbh was held in the state from April 1 to 30, and the notified area for the congregation covered various places in Haridwar, Dehradun and Tehri districts. The special investigation team (SIT) was constituted by Haridwar Senior Superintendent of Police Senthil Avoodai Krishna Raj S on Friday, a day after a case was registered against Max Corporate Service and private laboratories Dr Lalchandani Lab and Nalwa Laboratories for allegedly conducting the fake Covid tests during the Kumbh. The SIT has been constituted for a speedy probe, Krishna Raj said. Max Corporate Service and the two other labs have been booked under the Epidemic Act , the Disaster Management Act besides sections 120 B (criminal conspiracy to commit an offence punishable) and 420 (cheating) of the Indian Penal Co

Dr. Lal Pathlabs Ltd. is trading below its 30 day SMA of 3270.0

Dr. Lal Pathlabs Ltd.

25 May 2021

3179.60

1.66%

For Dr Lal PathLabs, rising non-covid revenues, expansion aid growth

livemint

Near-term weakness in the non-covid portfolio is expected to be offset by the spurt in covid and covid-associated test volumes with adequate testing capacity and further scaling up the testing bandwidth, say analysts at JM Financials

Dr. Lal Pathlabs Ltd. has an average target of 3111.40 from 5 brokers.

Dr. Lal Pathlabs Ltd.

25 May 2021

3179.60

1.66%

DR. LAL PATHLABS LIMITED

Hold: Dr. Lal Pathlabs Ltd.

Target

Geojit BNP Paribas

Dr. Lal PathLabs Limited provides diagnostic and related healthcare tests and services in India and internationally. Company has 231 clinical laboratories, including National Reference Lab at Delhi and Regional...

Dr. Lal Pathlabs Ltd. is trading below its 30 day SMA of 3270.0

Dr. Lal Pathlabs Ltd.

21 May 2021

3179.60

1.66%

Dr Lal PathLabs Q4 net profit jumps over 2.5 times to Rs 85.1 crore

Moneycontrol

The company had posted a net profit of Rs 32.6 crore for the corresponding period of the previous financial year, Dr Lal PathLabs said in a regulatory filing.